PYRAZOLINE HETEROCYCLIC: A REVIEW
AbstractPharmaceutical chemistry is devoted to the discovery and development of new agents for treating diseases. Inorganic compound continues to be important in therapy, for example, as antacids, mineral supplements, and radiopharmaceuticals, but organic molecules with increasingly specific pharma-cological activities are clearly dominant. The five and six-membered heterocyclic nitrogen-containing systems such as pyrazole, imidazole, trizoles, thiozolidine, pyrazolidine, etc., are far by the most important in the ongoing research for more efficacious drugs in the fields such as anti-bacterial, fungicidal, anti-inflammatory, anticonvulsant, diuretics, and anti-histaminic, etc. Pyrazoline is a five-membered heterocyclic compound having two adjacent nitrogen atoms within the ring. It has only one endocyclic double bond and is basic in nature. Pyrazole derivatives have a long history of application in agrochemicals and pharmaceutical industry as herbicides and active pharmaceuticals. The recent success of pyrazole COX-2 inhibitors has further highlighted the importance of these heterocyclic rings in medicinal chemistry. Many scientists have synthesized novel pyrazoline derivatives. They have characterized the synthesized compounds by thin-layer chromatographic technique and analyzed the spectrum by IR, NMR, Mass spectra. Some compounds had been synthesized by the microwave method of synthesis, which is more convenient than the normal method of synthesis. Pyrazoline is a unique template that is associated with several biological activities. This literature high lightened research work of many researchers reported in literature for different pharmacological activities on pyrazole and pyrazoline compounds synthesized.
Article Information
5
2570-2588
1204
1690
English
IJPSR
B. Dash and S. Karim *
Department of Pharmaceutical Analysis & Quality Assurance, Himalayan Pharmacy Institute, Majhitar, East Sikkim, India.
shajidulkarim451@gmail.com
01 May 2020
10 October 2020
12 April 2021
10.13040/IJPSR.0975-8232.12(5).2570-88
01 May 2021